tbuckley/cabot-search huggingface dataset:
Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node
Authors: Ulrike Leiter, Rudolf Stadler, Cornelia Mauch, Werner Hohenberger, Norbert H. Brockmeyer, Carola Berking, Cord Sunderkötter, Martin Kaatz, Kerstin Schatton, Percy Lehmann, Thomas Vogt, Jens Ulrich, Rudolf Herbst, Wolfgang Gehring, Jan-Christoph Simon, Ulrike Keim, Danielle Verver, Peter Martus, Claus Garbe
Journal: Journal of Clinical Oncology (2019)

PURPOSE We have previously reported on the 3-year results of the phase III German Dermatologic Cooperative Oncology Group trial (DeCOG; ClinicalTrials.gov identifier: NCT02434107 ) comparing distant metastasis-free survival (DMFS), recurrence-free survival (RFS), and overall survival (OS) in patients with positive sentinel lymph-node biopsy who were randomly assigned to complete lymph node dissection (CLND) or observation. Here, we report the final analysis with 72 months of median follow up. PATIENTS AND METHODS The multicenter randomized phase III trial included patients with cutaneous melanoma of the trunk and extremities who were randomly assigned (1:1) to undergo CLND or observation. DMFS was analyzed as the primary end point, and RFS, OS, and recurrences in the regional lymph node basin were secondary end points. The analysis was by intention to treat. Disease and survival information were collected quarterly. RESULTS From January 2006 to December 2014, 5,547 patients were screened to identify 1,256 with metastases in the sentinel lymph node (SLN). Of these, 483 (39%) were included: 241 in the observation arm and 242 in the CLND arm. In the final analysis, median follow up was 72 months (interquartile range, 67-77 months). No significant treatment-related difference was seen in the 5-year DMFS between the observation and CLND arms (67.6% v 64.9%, respectively; hazard ratio [HR], 1.08; P = .87). The 5-year RFS and OS also showed no difference (HR, 1.01 and 0.99, respectively). Grade 3 and 4 adverse effects occurred in 32 patients (13%) in the CLND arm; lymphedema (n = 20) and delayed wound healing (n = 5) were most common and no serious adverse events were reported. CONCLUSION The final results of the German Dermatologic Cooperative Oncology Group trial with a median follow up of 72 months showed higher event rates, but similar HRs compared with those at the 3-year analysis. These results confirm that immediate CLND in SLN-positive patients is not superior to observation in terms of DMFS, RFS, or OS and support not recommending CLND in patients with SLN metastasis.
TCT-372 The Impact of CHA2DS2-VASc and HAS-BLED Scores on Clinical Outcomes in the Amplatzer Amulet Observational Study
Authors: Giuseppe Tarantini, Gianpiero D'Amico, Boris Schmidt, Patrizio Mazzone, Sergio Berti, Sven Fischer, Juha Lund, Matteo Montorfano, Paolo Della Bella, Simon Lam, Ignacio Cruz-Gonzalez, Heyder Omran, Jens Erik Nielsen-Kudsk
Journal: Journal of the American College of Cardiology (2019)
TCT-418 Rates and Independent Correlates of 10-Year Major Adverse Events and Mortality in Patients Undergoing Left Main Revascularization
Authors: Tae Oh Kim, Sangwoo Park, Junho Hyun, Yeongjin Jeong, Junghoon Lee, Yujin Yang, KyungJin Choe, Hanbit Park, Sang-Cheol Cho, Euihong Ko, Do-Yoon Kang, Pil Hyung Lee, Jung-Min Ahn, Duk-Woo Park, Seung-Whan Lee, Seong-Wook Park, Seung-Jung Park
Journal: Journal of the American College of Cardiology (2019)
TCT-1 A Novel Risk-Based Strategy in Adopting New Technology: Pilot Study Assessing Clinical and Quality Outcomes of Real-World Intravascular Ultrasound (IVUS) and Instant Wave-Free Ratio (iFR) Utilization in a Unique Risk-Sharing Program
Authors: Mark Chang, Timothy Attebery, Mark Aziz, Puran Bhagat, Jerry Blackwell, Nicholas Havers, Thomas Helton, Lori Jackson, Roberta Kramer, Herbert Ladley, Jin Liu, Marc Mayhew, Chris Metzger, Kristen Richards, Pabitra Saha, Daniel Simpson, Brian Fennel
Journal: Journal of the American College of Cardiology (2019)
TCT-700 Impact of Pulmonary Hypertension and COPD on Outcomes After Transcatheter Aortic Valve Replacement - A Report From the STS/ACC TVT Registry
Authors: Joao Cavalcante, John Schindler, Ibrahim Sultan, Sreekanth Vemulapalli, Dustin Kliner, Ajay Jayant Kirtane, Vinod Thourani, Thomas Gleason
Journal: Journal of the American College of Cardiology (2019)
Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma
Authors: Michael Wang, Simon Rule, Pier Luigi Zinzani, Andre Goy, Olivier Casasnovas, Stephen D. Smith, Gandhi Damaj, Jeanette K. Doorduijn, Thierry Lamy, Franck Morschhauser, Carlos Panizo, Bijal Shah, Andrew Davies, Richard Eek, Jehan Dupuis, Eric Jacobsen, Arnon P. Kater, Steven Le Gouill, Lucie Oberic, Tadeusz Robak, Preetesh Jain, Melanie M. Frigault, Raquel Izumi, Dorothy Nguyen, Priti Patel, Ming Yin, Monika Długosz-Danecka
Journal: Leukemia (2019)
Esophagobronchial fistula after sleeve gastrectomy successfully treated by endoscopic submucosal dissection and over-the-scope clip
Authors: Marina Ciochina, Miruna Cruceru, Jérôme Rivory, Maud Robert, Nada Nargues, Arnaud Pasquer, Mathieu Pioche
Journal: Endoscopy (2019)

Sleeve gastrectomy is a simple bariatric procedure that can sometimes be associated with serious complications. Among these, gastrobronchial or esophagobronchial fistula is rare (its incidence is 0.2 %) but is challenging to treat, frequently leading to left lower lobectomy [1]. To the best of our knowledge, successful endoscopic management of such a fistula following bariatric surgery has never been reported.
TCT-767 Safety and Feasibility of Same Day Discharge Using the Vancouver PFO/ASD Clinical Pathway
Authors: Madeleine Barker, Janarthanan Sathananthan, Jacqueline Saw, Sandra Lauck, Philip Teal, Peter Fahmy, Thomas Gilhofer, Ashkan Parsa, Ali Alsulaimi, Mark Hensey, Abdullah Alkhodair, Uri Landes, John Webb, David Wood
Journal: Journal of the American College of Cardiology (2019)
Treatment of Ovarian Cancer With Intraperitoneal Platinum: Heating Up the Debate
Authors: Emiel A. De Jaeghere, Félix B. Gremonprez, Philippe G. Tummers, Wouter C. Willaert, Wim P. Ceelen, Frédéric C. Amant, Hannelore G. Denys
Journal: Journal of Clinical Oncology (2019)
TCT-735 Comparative Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Old Infarct
Authors: Ayman Elbadawi, Marwan Saad, Islam Elgendy, Karim Mahmoud, Kirolos Barssoum, Mohamed Omer, Mohamed Hamed, Gbolahan Ogunbayo, Hani Jneid
Journal: Journal of the American College of Cardiology (2019)
TCT-609 Use of Iso-Osmolar Contrast Media in High AKI Risk Patients Undergoing Endovascular Abdominal Aortic Aneurysm Repair (EVAR) Is Associated With Lower Incidence of Major Adverse Renal or Cardiac Events (MARCE)
Authors: Amit Amin, Anand Prasad, Michael Ryan, Candace Gunnarsson, Emmanouil Brilakis
Journal: Journal of the American College of Cardiology (2019)
Testing the Feasibility of SentiMag/Sienna+ for Detecting Inguinal Sentinel Nodes in Penile Cancer (SentiPen): An eUROGEN and National Cancer Research Institute Trial
Authors: Paul Cleaveland, Maurice Lau, Arie Parnham, Brian Murby, David Ashworth, Prakash Manohoran, Ben Taylor, Jon Bell, Pavan Najran, Pedro Oliveira, Jonathan Shanks, Vijay Sangar
Journal: European Urology (2019)
APOL1 Kidney Risk Variants Induce Cell Death via Mitochondrial Translocation and Opening of the Mitochondrial Permeability Transition Pore
Authors: Shrijal S. Shah, Herbert Lannon, Leny Dias, Jia-Yue Zhang, Seth L. Alper, Martin R. Pollak, David J. Friedman
Journal: Journal of the American Society of Nephrology (2019)

Genetic Variants in Apolipoprotein L1 (APOL1) are associated with large increases in CKD rates among African Americans. Experiments in cell and mouse models suggest that these risk-related polymorphisms are toxic gain-of-function variants that cause kidney dysfunction, following a recessive mode of inheritance. Recent data in trypanosomes and in human cells indicate that such variants may cause toxicity through their effects on mitochondria.To examine the molecular mechanisms underlying APOL1 risk variant-induced mitochondrial dysfunction, we generated tetracycline-inducible HEK293 T-REx cells stably expressing the APOL1 nonrisk G0 variant or APOL1 risk variants. Using these cells, we mapped the molecular pathway from mitochondrial import of APOL1 protein to APOL1-induced cell death with small interfering RNA knockdowns, pharmacologic inhibitors, blue native PAGE, mass spectrometry, and assessment of mitochondrial permeability transition pore function.We found that the APOL1 G0 and risk variant proteins shared the same import pathway into the mitochondrial matrix. Once inside, G0 remained monomeric, whereas risk variant proteins were prone to forming higher-order oligomers. Both nonrisk G0 and risk variant proteins bound components of the mitochondrial permeability transition pore, but only risk variant proteins activated pore opening. Blocking mitochondrial import of APOL1 risk variants largely eliminated oligomer formation and also rescued toxicity.Our study illuminates important differences in the molecular behavior of APOL1 nonrisk and risk variants, and our observations suggest a mechanism that may explain the very different functional effects of these variants, despite the lack of consistently observed differences in trafficking patterns, intracellular localization, or binding partners. Variant-dependent differences in oligomerization pattern may underlie APOL1's recessive, gain-of-function biology.
High-dose melphalan (MEL) based autotransplants (AT) for multiple myeloma (MM): The Arkansas experience since 1989 in more than 2,800 patients
Authors: M. Pineda-Roman, J. Haessler, K. Hollmig, E. Anaissie, F. van Rhee, M. Zangari, G. Tricot, A. Mohiuddin, J. Crowley, B. Barlogie
Journal: Journal of Clinical Oncology (2007)

8043 Background: The dose-response effect for MEL has been safely exploited through the use of AT. Long-term follow-up studies from large centers are critical to understand who benefits most and who should be considered for alternative treatment approaches. Methods: 2,836 patients receiving at least one MEL AT were considered. Kaplan-Meier analysis was used to estimate median event-free survival (EFS) and overall survival (OS). Cox regression was used to evaluate independent prognostic factors of EFS and OS from AT. Results: Of the 2,836 patients, 979 were enrolled into front-line Total Therapy protocols 1/2/3 (TT); 1,064 were entered on protocols for previously treated patients (non-TT); and 793 were treated off protocol (non-P). Overall median EFS and OS from 1 st AT are 31mo and 53 mo; 10-yr EFS and OS were 19% and 24%; 15% survived &gt;15 yr. The 5 strongest favorable OS features included TT (HR 0.46, p&lt;0.001), absence of cytogenetic abnormalities (no CA) (HR 0.48, p&lt;0.001), B2M &lt;3 mg/L (HR 0.46, p&lt;0.001), albumin &gt;=3g/dL (HR 0.45, p&lt;0.001) and platelet count &gt;=100.000/microL (HR 0.41, p&lt;.001), so that 10-yr OS rates were 58% with 5, 24% with 4, 16% with 3, 4% with 2 and 0% with =&lt;1 favorable parameter (p&lt;0.0001). The corresponding median durations of EFS were 80 mo, 37 mo, 27 mo, 18 mo and 7 mo (p&lt;0.0001). Conclusion: This large single institution experience demonstrates that &gt; 10 yr OS can be accomplished in over one-half of the 16% of all patients presenting without CA, with low levels of B2M and albumin, high platelet count and receiving TT. The worst constellation affected 3% of all patients presenting with at most 1 good-risk feature whose 5-yr survival was only 7%. These data should serve as guidepost for MM investigators and patients alike, against which newer treatments should be measured. No significant financial relationships to disclose.
“I Don’t Want to Go on Living This Way”: Desire for Hastened Death and the Ethics of Involuntary Hospitalization
Authors: Kasia Tolwinski, Andrei Nemoianu, Andreea Bucaloiu, Joseph Venditto, F. Daniel Davis, Jennifer K. Wagner
Journal: The American Journal of Bioethics (2019)

This article refers to:Reweighing the Ethical Tradeoffs in the Involuntary Hospitalization of Suicidal Patients
Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study
Authors: Nam Hoon Kim, Ki Hoon Han, Jimi Choi, Juneyoung Lee, Sin Gon Kim
Journal: BMJ (2019)

Abstract Objective To investigate whether fenofibrate as add-on to statin treatment reduce persistent cardiovascular risk in adults with metabolic syndrome in a real world setting. Design Propensity matched cohort study. Setting Population based cohort in Korea. Participants 29 771 adults with metabolic syndrome (≥40 years) receiving statin treatment. 2156 participants receiving combined treatment (statin plus fenofibrate) were weighted based on propensity score in a 1:5 ratio with 8549 participants using statin only treatment. Main outcome measure Primary outcome was composite cardiovascular events including incident coronary heart disease, ischaemic stroke, and death from cardiovascular causes. Results The incidence rate per 1000 person years of composite cardiovascular events was 17.7 (95% confidence interval 14.4 to 21.8) in the combined treatment group and 22.0 (20.1 to 24.1) in the statin group. The risk of composite cardiovascular events was significantly reduced in the combined treatment group compared with statin group (adjusted hazard ratio 0.74, 95% confidence interval 0.58 to 0.93; P=0.01). The significance was maintained in the on-treatment analysis (hazard ratio 0.63, 95% confidence interval 0.44 to 0.92; P=0.02). The risk of incident coronary heart disease, ischaemic stroke, and cardiovascular death was lower in the combined treatment group than statin group but was not significant. Participant characteristics did not appear to be associated with the low risk of composite cardiovascular events with combined treatment. Conclusion In this propensity weighted cohort study of adults with metabolic syndrome, the risk of major cardiovascular events was significantly lower with fenofibrate as add-on to statin treatment than with statin treatment alone.
TCT-729 Short-Term Outcomes with Transcatheter vs. Surgical Aortic Valve Replacement in Low-Risk Patients: A Meta-Analysis of Randomized Controlled Trials
Authors: Amartya Kundu, Partha Sardar, Rohit Malhotra, Waqas Qureshi, Nikolaos Kakouros
Journal: Journal of the American College of Cardiology (2019)
Correction: Antiphospholipid syndrome
Authors: Karen Schreiber, Savino Sciascia, Philip G. de Groot, Katrien Devreese, Soren Jacobsen, Guillermo Ruiz-Irastorza, Jane E. Salmon, Yehuda Shoenfeld, Ora Shovman, Beverley J. Hunt
Journal: Nature Reviews Disease Primers (2018)
Parity Arguments for ‘Physician Aid-in-Dying’ (PAD) for Psychiatric Disorders: Their Structure and Limits
Authors: Marie E. Nicolini, Chris Gastmans, Scott Y. H. Kim
Journal: The American Journal of Bioethics (2019)

Kious and Battin (K&B) argue that psychiatric PAD (PPAD) should be legal in the US, based on a ‘parity’ argument (Kious and Battin 2019). This is the most popular approach to argue for PPAD (Cholbi...
Feasibility and safety of ultra-low tidal volume ventilation without extracorporeal circulation in moderately severe and severe ARDS patients
Authors: J C Richard, S Marque, A Gros, M Muller, G Prat, G Beduneau, J P Quenot, J Dellamonica, R Tapponnier, E Soum, L Bitker, J Richecoeur
Journal: Intensive Care Medicine (2019)
Iron Chelation as a Potential Therapeutic Strategy for AKI Prevention
Authors: Shreyak Sharma, David E. Leaf
Journal: Journal of the American Society of Nephrology (2019)

AKI remains a major public health concern. Despite years of investigation, no intervention has been demonstrated to reliably prevent AKI in humans. Thus, development of novel therapeutic targets is urgently needed. An important role of iron in the pathophysiology of AKI has been recognized for over three decades. When present in excess and in nonphysiologic labile forms, iron is toxic to the kidneys and multiple other organs, whereas iron chelation is protective across a broad spectrum of insults. In humans, small studies have investigated iron chelation as a novel therapeutic strategy for prevention of AKI and extrarenal acute organ injury, and have demonstrated encouraging initial results. In this review, we examine the existing data on iron chelation for AKI prevention in both animal models and human studies. We discuss practical considerations for future clinical trials of AKI prevention using iron chelators, including selection of the ideal clinical setting, patient population, iron chelating agent, and dosing regimen. Finally, we compare the key differences among the currently available iron chelators, including pharmacokinetics, routes of administration, and adverse effects.
TCT-68 Influence of Final Kissing Balloon Inflation on Long-Term Outcomes After PCI of Distal Left Main Bifurcation Lesions: Analysis From the EXCEL Trial
Authors: Annapoorna Kini, George Dangas, Usman Baber, Yuliya Vengrenyuk, David Kandzari, Martin Leon, Marie-Claude Morice, Patrick Serruys, A. Pieter Kappetein, Joseph Sabik, Ovidiu Dressler, Roxana Mehran, Samin Sharma, Gregg Stone
Journal: Journal of the American College of Cardiology (2019)
Children with cancer are missing out on precision medicine, study finds
Authors: Shivali Fulchand
Journal: BMJ (2019)

Only a small number of children with solid tumour cancers are able to access targeted precision medicine that is already available for adults, a study has found.

Researchers from the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust in London set out to evaluate whether their methods of DNA analysis could inform clinical treatment in young people with solid tumours.

Precision medicine uses DNA sequencing to identify gene mutations for targeted cancer treatment and is included in the NHS long term plan to try to improve cancer outcomes in England. Precision medicine is specific and minimises side effects.

For their study the researchers checked for 91 common cancer genes in 255 samples from …
TCT-330 Accuracy of an Interactive FFRCT Planner for the Evaluation of Post-PCI FFR
Authors: Michiel Bom, Stefan Schumacher, Roel Driessen, Pepijn van Diemen, Henk Everaars, Peter van de Ven, Albert van Rossum, Ralf Sprengers, Niels Verouden, Alexander Nap, Jonathon Leipsic, Ibrahim Danad, Charles Taylor, Paul Knaapen
Journal: Journal of the American College of Cardiology (2019)
MicroRNA‐210 Promotes Bile Acid–Induced Cholestatic Liver Injury by Targeting Mixed‐Lineage Leukemia‐4 Methyltransferase in Mice
Authors: Young‐Chae Kim, Hyunkyung Jung, Sunmi Seok, Yang Zhang, Jian Ma, Tiangang Li, Byron Kemper, Jongsook Kim Kemper
Journal: Hepatology (2019)

Bile acids (BAs) are important regulators of metabolism and energy balance, but excess BAs cause cholestatic liver injury. The histone methyltransferase mixed-lineage leukemia-4 (MLL4) is a transcriptional coactivator of the BA-sensing nuclear receptor farnesoid X receptor (FXR) and epigenetically up-regulates FXR targets important for the regulation of BA levels, small heterodimer partner (SHP), and bile salt export pump (BSEP). MLL4 expression is aberrantly down-regulated and BA homeostasis is disrupted in cholestatic mice, but the underlying mechanisms are unclear.We examined whether elevated microRNA-210 (miR-210) in cholestatic liver promotes BA-induced pathology by inhibiting MLL4 expression. miR-210 was the most highly elevated miR in hepatic SHP-down-regulated mice with elevated hepatic BA levels. MLL4 was identified as a direct target of miR-210, and overexpression of miR-210 inhibited MLL4 and, subsequently, BSEP and SHP expression, resulting in defective BA metabolism and hepatotoxicity with inflammation. miR-210 levels were elevated in cholestatic mouse models, and in vivo silencing of miR-210 ameliorated BA-induced liver pathology and decreased hydrophobic BA levels in an MLL4-dependent manner. In gene expression studies, SHP inhibited miR-210 expression by repressing a transcriptional activator, Kruppel-like factor-4 (KLF4). In patients with primary biliary cholangitis/cirrhosis (PBC), hepatic levels of miR-210 and KLF4 were highly elevated, whereas nuclear levels of SHP and MLL4 were reduced.Hepatic miR-210 is physiologically regulated by SHP but elevated in cholestatic mice and patients with PBC, promoting BA-induced liver injury in part by targeting MLL4. The miR-210-MLL4 axis is a potential target for the treatment of BA-associated hepatobiliary disease.
TCT-563 Improved Remodelling With TEVAR and Distal Bare Metal Stent (PETTICOAT) in Patients With Acute Complicated Type B Aortic Dissection: 1-Year Results of a Multicentre Study in Survivors of Type B Aortic Dissection Undergoing Stenting (ASSIST)
Authors: Xun Yuan, Christoph Nienaber, Mohamad Aboukoura
Journal: Journal of the American College of Cardiology (2019)
Longer Survival With Anti–Programmed Cell Death 1 and Development of Cutaneous Toxic Effects, an Expected Association
Authors: Marko Skelin, Marko Lucijanic
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Landscape of stimulation-responsive chromatin across diverse human immune cells
Authors: Diego Calderon, Michelle L. T. Nguyen, Anja Mezger, Arwa Kathiria, Fabian Müller, Vinh Nguyen, Ninnia Lescano, Beijing Wu, John Trombetta, Jessica V. Ribado, David A. Knowles, Ziyue Gao, Franziska Blaeschke, Audrey V. Parent, Trevor D. Burt, Mark S. Anderson, Lindsey A. Criswell, William J. Greenleaf, Alexander Marson, Jonathan K. Pritchard
Journal: Nature Genetics (2019)
TCT-200 Reduced Radiation Exposure in the Cardiac Catheterization Laboratory Using Combination of both Horizontal and a Novel Vertical Radiation Shield
Authors: Carmelo Panetta, Marat Yanavitski, Erin Galbraith, Patrick Koller, Sunil Rao, Binita Shah, Sohah Iqbal
Journal: Journal of the American College of Cardiology (2019)
The First Registry for Patients with Congenital Dyserythropoietic Anemia in North America: Design and Preliminary Results
Authors: Omar Niss, Robert B. Lorsbach, Georgios E Christakopoulos, Lisa Trump, Megan Reynolds, Katie Giger, Clarissa E. Johnson, Ammar Husami, David K. Buchbinder, Jennifer A. Rothman, Gavin D. Roach, Adrienne Lee, Vinod Gidvani-Diaz, Morgan L. McLemore, Satheesh Chonat, Adam S. Nelson, James B. Ball, Bruce J. Aronow, Carolyn Lutzko, Kejian Zhang, Theodosia A. Kalfa
Journal: Blood (2017)
TCT-296 Comparison Between the Use of Very Long Stents and Overlapping Stents for the Treatment of Diffuse Coronary Artery Disease: A Real-Life Registry
Authors: José Abellán-Huerta, Martin Negreira-Caamaño, Alfonso Jurado-Román, Ignacio Sanchez-Perez, María López-Lluva, Pedro Pérez-Díaz, Juan Antonio Requena, Jesus Piqueras-Flores, Jorge Martinez del Río, Fernando Lozano
Journal: Journal of the American College of Cardiology (2019)